CALR3 inhibitors belong to a distinctive chemical class characterized by their ability to selectively target and modulate the activity of CALR3, a calcium-binding protein crucial for various cellular functions. CALR3, short for Calreticulin 3, is a member of the calreticulin family, primarily localized within the endoplasmic reticulum (ER) of eukaryotic cells. This protein is involved in the regulation of calcium homeostasis, chaperoning the folding of newly synthesized glycoproteins, and contributing to cellular stress responses. CALR3 inhibitors exert their effects by binding to specific sites on CALR3, thereby influencing its conformational changes and subsequently altering its interactions with other cellular components. The modulation of CALR3 activity through inhibition holds promise for elucidating the intricate regulatory networks governing cellular processes, shedding light on the broader significance of this protein in cellular physiology.
CALR3 inhibitors class enables researchers to explore a range of chemical scaffolds and design strategies to enhance potency and selectivity. Understanding the precise mechanisms by which these inhibitors interact with CALR3 may provide valuable insights into the fundamental biology of calcium signaling and protein folding within the ER. Moreover, the development of CALR3 inhibitors serves as a valuable tool for probing the intricate web of cellular pathways, facilitating a deeper comprehension of the molecular underpinnings of various physiological and pathological conditions. As research progresses, the exploration of CALR3 inhibitors continues to contribute to the ever-expanding knowledge of cellular biology, paving the way for potential applications in various scientific fields.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker that can inhibit calcium influx, potentially affecting CALR3-related calcium signaling. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Another calcium channel blocker that can modulate the release of calcium from intracellular stores, possibly influencing CALR3 interaction with calcium. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor, which can increase cytosolic calcium concentration and may disrupt CALR3-related calcium homeostasis. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
RyR receptor modulator that can perturb calcium release from the sarcoplasmic reticulum, potentially affecting CALR3’s function. | ||||||
TMB-8 • HCl | 53464-72-5 | sc-3522 sc-3522A | 10 mg 50 mg | $43.00 $129.00 | 10 | |
Blocks intracellular calcium release and may indirectly influence CALR3-associated pathways. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
Inhibits myosin light-chain kinase (MLCK) and can affect calcium signaling, which may indirectly alter CALR3’s activity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
L-type calcium channel blocker, can prevent calcium entry and might indirectly modulate CALR3 function. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Similarly to Nifedipine, this drug can block L-type calcium channels affecting calcium-dependent processes linked to CALR3. | ||||||
Bepridil | 64706-54-3 | sc-507400 | 100 mg | $1620.00 | ||
Blocks both calcium and potassium channels, potentially altering signaling pathways that CALR3 is part of. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
Inhibits receptor-mediated calcium entry, which could indirectly influence CALR3 activity. | ||||||